Zachodniopomorskie Centrum Onkologii
- Address
- lock Available on a paid plan
Zachodniopomorskie Centrum Onkologii - Advanced Oncology Research Center
Zachodniopomorskie Centrum Onkologii is a specialized oncology research center conducting cutting-edge clinical trials across multiple cancer types. The center demonstrates particular expertise in breast cancer therapeutics, prostate cancer treatment, and advanced melanoma, with a strong focus on precision medicine approaches and novel immunotherapy combinations.
- Breast cancer research including hormone receptor-positive, HER2-negative, triple-negative, and BRCA-mutated subtypes with targeted therapies and personalized treatment strategies
- Advanced prostate cancer investigations, particularly metastatic castration-resistant and castration-sensitive disease with hormonal agents and novel therapeutics
- Immunotherapy trials combining checkpoint inhibitors with targeted agents and cancer vaccines
- Precision oncology utilizing molecular profiling, ctDNA detection, and gene expression-driven treatment decisions
The center actively participates in international Phase Ib through Phase III trials evaluating combination therapies including CDK4/6 inhibitors, PARP inhibitors, and immunotherapeutic approaches. Research initiatives emphasize risk stratification, residual disease management, and the development of personalized treatment strategies for patients with advanced and metastatic cancers, positioning the center at the forefront of modern oncology research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 56 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 56 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Merck Sharp & Dohme LLC3active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Zachodniopomorskie Centrum Onkologii
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Open-label Study of Opevesostat Tosylate Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | Merck Sharp & Dohme LLC | Phase III | Recruiting | Apr 2024 | — |
IMP list
lock Showing 1 of 56 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 4 | Unknown | 2023-08-01 | 2024-07-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.